In 2013, the FDA issued a warning letter to 23andMe requiring that it stop marketing its DTC Personal Genome Service. The FDA had concluded that the $99 saliva test was a class III medical device requiring FDA approval. But a little less than two years later, the company won FDA approval for a DTC genetic carrier test for Bloom Syndrome.